BioCryst Pharmaceuticals-Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

BioCryst Pharmaceuticals (BCRX) closed the last trading session at $8.28, gaining 4.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 15.25 indicates an 84.2% upside potential.The average comprises 12 short-term price targets ranging from a low of $8 to a high of$ 30, with a standard deviation of $6.48. While the lowest estimate indicates a decline of 3.4% from the current price ...